secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2023-06-07T23:59:59+00:00
Accession:  0000950170-23-026739
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta EDP-235 shows 0.8-1.0 log viral load decline in Phase 2 COVID-19 trial subset
--------------------------------------------------------------------------------

- In nucleocapsid-negative patients, 400mg EDP-235 showed 0.8 log viral load decline vs placebo at Day 5.
- In subset treated within 3 days of symptom onset, 1.0 log viral load decline seen at Day 5.
- Results support further development of EDP-235 for COVID-19.
- Updated corporate presentation with additional SPRINT analyses posted on website June 7, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000095017023026739/0000950170-23-026739-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000095017023026739/enta-20230607.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-026739

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer